Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Li Watsek
CANT
Li Watsek
Cantor Fitzgerald
Wall Street Analyst
★★★☆☆
#1255
on 13Foresight · ranked by our own returns
55%
Success Rate
+22.9%
Average Return
11 of 20 calls profitable · +8.2% vs benchmark
📈 Across the calls we could measure, roughly 55% of Li Watsek's ratings turned a profit when each position was held for 1 year — averaging +22.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 5 Hold 0 Sell
Li's Stock Coverage 24 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
FTH
Faeth Therapeutics
 Jun 03, 2026 BUY Strong Buy
+107.4% avg upside
11 analysts
 — ·
ZLAB
Zai Lab
 Apr 29, 2026 BUY Strong Buy
+223.0% avg upside
13 analysts
$37.00
103.52% Upside
 -17.7%
REPL
Replimune Group
 Apr 10, 2026 HOLD Hold
+72.3% avg upside
13 analysts
 — +114.1%
ASND
Ascendis Pharma
 Apr 01, 2026 BUY Strong Buy
+16.9% avg upside
24 analysts
$300.00
29.90% Upside
 -2.2%
CRIS
Curis
 Mar 27, 2026 HOLD Strong Buy
+1938.0% avg upside
12 analysts
 — -25.0%
TYRA
Tyra Bioscience
 Mar 04, 2026 BUY Strong Buy
+57.9% avg upside
17 analysts
 — +3.9%
AVBP
ArriVent BioPharma, Inc.
 Dec 22, 2025 BUY Strong Buy
+37.1% avg upside
15 analysts
 — +40.0%
CMPX
Compass Therapeutics
 Dec 03, 2025 BUY Strong Buy
+372.3% avg upside
19 analysts
 — +0.9%
RCUS
Arcus Biosciences
 Oct 08, 2025 BUY Strong Buy
+38.0% avg upside
20 analysts
 — +60.6%
CNTX
Context Therapeutics
 Oct 02, 2025 BUY Strong Buy
+879.2% avg upside
12 analysts
 — +116.0%
ARVN
Arvinas Holding Company
 Sep 18, 2025 BUY Buy
+265.4% avg upside
27 analysts
 — -1.8%
IDYA
IDEAYA Biosciences
 Sep 09, 2025 BUY Strong Buy
+55.3% avg upside
29 analysts
 — +26.4%
KURA
Kura Oncology
 Jun 26, 2025 BUY Strong Buy
+162.8% avg upside
26 analysts
 — +67.0%
CRVS
Corvus Pharmaceuticals
 Jun 12, 2025 BUY Strong Buy
+114.4% avg upside
14 analysts
 — +181.4%
ACRV
Acrivon Therapeutics, Inc.
 May 15, 2025 BUY Strong Buy
+818.9% avg upside
13 analysts
 — +60.9%
AFMDQ
Affimed
 May 14, 2025 HOLD Buy
+12648900.0% avg upside
15 analysts
 — ·
TARA
Protara Therapeutics
 Mar 14, 2025 BUY Strong Buy
+1153.9% avg upside
21 analysts
 — +22.0%
ALXO
ALX Oncology Holdings
 Jan 24, 2025 BUY Strong Buy
+1086.5% avg upside
11 analysts
 — -7.6%
BCYC
Bicycle Therapeutics
 Jun 03, 2024 BUY Strong Buy
+504.5% avg upside
20 analysts
 — -64.0%
ALP
Alpha Compute
 Aug 30, 2023 BUY Strong Buy
+8018.9% avg upside
6 analysts
$11.00
4321.25% Upside
 ·
FATE
Fate Therapeutics
 Aug 09, 2023 HOLD Buy
+492.3% avg upside
31 analysts
$5.00
139.18% Upside
 -0.9%
TSE:APS
Aptose Biosciences
 Jun 11, 2023 BUY Strong Buy
+4059.2% avg upside
10 analysts
$53.19
2232.93% Upside
 ·
NKTX
Nkarta
 Aug 12, 2022 BUY Strong Buy
+554.9% avg upside
15 analysts
$38.00
1228.60% Upside
 -88.5%
SLS
SELLAS Life Sciences Group
 Jun 28, 2022 BUY Strong Buy
+768.3% avg upside
15 analysts
$6.00
25.43% Downside
 -26.7%
🔒 19 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Li Watsek — Frequently Asked Questions
How accurate are Li Watsek's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Li's ratings were profitable over a one-year hold, with an average return of +22.8% per rating, or +8.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Li ranked on 13Foresight?
Li Watsek is currently ranked #1255 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Li cover?
Li most recently has ratings on FTH, ZLAB, REPL, ASND, CRIS, TYRA, AVBP, CMPX, RCUS, CNTX, ARVN, IDYA and 12 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.